존슨 & Johnson on Friday said its single-shot 코로나 바이러스 vaccine was 72% effective in preventing moderate-to-severe COVID-19 in the U.S, but fell to 66% in a larger trial conducted worldwide. The results stem from a Phase 3 ENSEMBLE clinical trial, which involved 43,783 participants.
The shot was found to be 66% effective in preventing moderate-to-severe illness in Latin America, 과 57% effective in South Africa at 28 days post-vaccination.
J&J’s vaccine differs from currently approved jabs in the U.S. in that it requires a single shot as opposed to two doses, and was created using an adenovirus rather than mRNA technology.
“존슨 & Johnson embarked on the global effort to combat the COVID-19 pandemic a year ago, and has brought the full force of our capabilities, as well as tremendous public-private partnerships, to enable the development of a single-shot vaccine. Our goal all along has been to create a simple, effective solution for the largest number of people possible, and to have maximum impact to help end the pandemic,” Alex Gorsky, Chairman, Board of Directors and Chief Executive Officer, 존슨 & 존슨 said in a press release Friday. “We’re proud to have reached this critical milestone and our commitment to address this global health crisis continues with urgency for everyone, everywhere.”
이것은 발전하는 이야기입니다. Check back for updates.